Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 17, 2026

Lilly agrees to acquire Calytrix Bio for $1.5bn

Eli Lilly has agreed to acquire Calytrix Bio in a deal valued at up to $1.5bn to advance an investigational biparatopic antibody targeting mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF).

The agreement between Lilly and Calytrix Bio will advance a new biparatopic antibody targeting mCALR-driven ET and MF. Credit: Felix Geringswald/Shutterstock.com.